Personality trait neuroticism decreased (P < 0.0001) and trait extraversion increased (P < 0.01) compared with study inclusion. Individuals attributed positive long-term effects to the psychedelic experience.  Conclusions Patients reported sustained long-term effects of LSD-assisted therapy for anxiety.

This study enhances our understanding of the LSD effect on the architecture and neural behavior of pain in healthy subjects and provides great promise for future research in the field of cognitive science and pharmacology.

As of 2024, some psychedelics have been given a legal or decriminalised foothold in: parts of Central Africa (Equatorial Guinea, Cameroon and Republic of the Congo), South Africa, Australia, the Bahamas, Brazil, the British Virgin Islands, Canada, the Czech Republic, Costa Rica, Israel, Jamaica, Mexico, Nepal, the Netherlands, Panama, Peru, Portugal, Samoa, Spain, Switzerland and the United States. 

In the long shadow of federal prohibition, a market for psychedelic shroom products is flourishing—and it’s rife with counterfeits and adulterants.

Psilocybin caused persistent decrease in functional connectivity between the anterior hippocampus and default mode network, lasting for weeks. Persistent reduction of hippocampal-default mode network connectivity may represent a neuroanatomical and mechanistic correlate of the proplasticity and therapeutic effects of psychedelics.

In this warm, informative podcast, our very own Dr Duncan Still is interviewed by Prof David Nutt of DrugScience (and many other ventures). Duncan talks about his own journey into medicine and particularly his passion for teaching more integrative approaches to health & healing.

Participants who reported lifetime co-use of cannabis and psychedelics (N = 63) were asked open-ended questions about their most recent simultaneous co-use experience.

PAP offers a promising avenue for a deeper understanding and therapeutic resolution of traumatic dissociation, which could fundamentally improve the treatment paradigm for many trauma-related disorders.

In this essay, we aim to explore the benefits and risks of integration groups, and offer a preliminary set of guidelines to physicians, researchers and individuals to help assess and evaluate these groups

Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing.

This newsy article links to 7 recent psilocybin studies on alcohol use disorder, anorexia, long Covid, learning, brain connectivity, auditory perception and cluster headaches.

Searches for microdosing in the US remained stable until 2014, then increased annually thereafter, with a cumulative increase by a factor of 13.4 from 2015 to 2023 (7.9 per 10 million to 105.6 per 10 million searches, respectively). In 2023, there were 3.0 million microdosing searches in the US.

How much of this sometimes life-altering experience is chemical and empirical, and how much is mental and subjective?

Within the class of drugs generally classified as psychedelics, psilocybin has the highest past-year and past-month prevalence rates among U.S. adults. Of those ages 18 and older, 3.1 percent — or approximately 8 million people — used psilocybin in 2023.

The Dutch government should allow treatment with ecstasy chemical MDMA for people with post-traumatic stress disorder (PTSD), an advisory body set up to look at the issue has recommended.

Even after selecting patients who initially responded to ketamine, 59.5 percent of the enriched participants still dropped out of the trial before its completion, largely due to a lack of efficacy.

Can the acute subjective effects of classic psychedelics be dissociated from their sustained therapeutic properties? Several plausible clinical scenarios are proposed to offer clarity on and potentially answer this question.

A global reference on drug markets, trends and policy developments, the World Drug Report offers a wealth of data and analysis and in 2024 comprises several elements tailored to different audiences.

Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration.

Psychedelic Alpha issued a helpful discussion of both the Institute for Clinical & Economic Review's Final Evidence Report and Lykos Therapeutic's response.